A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

NCT05682638 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

34000

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL: LVRNA009
OTHER: 0.9%NaCl

Sponsor

AIM Vaccine Co., Ltd.

Collaborators

[object Object]
[object Object]
[object Object]